Nuvalent (NUVL) Stock Forecast, Price Target & Predictions
NUVL Stock Forecast
Nuvalent stock forecast is as follows: an average price target of $107.33 (represents a 22.73% upside from NUVL’s last price of $87.45) and a rating consensus of 'Buy', based on 4 wall street analysts offering a 1-year stock forecast.
NUVL Price Target
NUVL Analyst Ratings
Nuvalent Price Target by Analyst
Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
---|---|---|---|---|---|---|
Jul 10, 2024 | Bradley Canino | Stifel Nicolaus | $115.00 | $73.63 | 56.19% | 31.50% |
Apr 17, 2024 | Roger Song | Jefferies | $97.00 | $64.75 | 49.81% | 10.92% |
Apr 01, 2024 | Christopher Liu | Leerink Partners | $110.00 | $75.09 | 46.49% | 25.79% |
Nuvalent Price Target by Period
1M | 3M | 12M | |
---|---|---|---|
# Anlaysts | - | 1 | 3 |
Avg Price Target | - | $115.00 | $107.33 |
Last Closing Price | $87.45 | $87.45 | $87.45 |
Upside/Downside | -100.00% | 31.50% | 22.73% |
Analyst Ratings Upgrades/Downgrades
Date | Company | Previous Rating | New Rating | Rating Change |
---|---|---|---|---|
Aug 29, 2024 | Barclays | - | Overweight | Initialise |
Apr 17, 2024 | Jefferies | - | Buy | Initialise |
Apr 01, 2024 | Leerink Partners | - | Outperform | Upgrade |
Aug 08, 2023 | SVB Leerink | - | Outperform | Initialise |
Nuvalent Financial Forecast
Nuvalent Revenue Forecast
Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
---|---|---|---|---|---|---|---|
Revenue | - | - | - | - | - | - | - |
Avg Forecast | $12.50M | $666.67K | - | - | - | - | - |
High Forecast | $12.50M | $666.67K | - | - | - | - | - |
Low Forecast | $12.50M | $666.67K | - | - | - | - | - |
# Analysts | - | - | - | - | - | - | - |
Surprise % | - | - | - | - | - | - | - |
Nuvalent EBITDA Forecast
Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
---|---|---|---|---|---|---|---|
# Analysts | - | - | - | - | - | - | - |
EBITDA | - | - | - | - | - | - | - |
Avg Forecast | - | - | - | - | - | - | - |
High Forecast | - | - | - | - | - | - | - |
Low Forecast | - | - | - | - | - | - | - |
Surprise % | - | - | - | - | - | - | - |
Nuvalent Net Income Forecast
Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
---|---|---|---|---|---|---|---|
# Analysts | - | - | - | - | - | - | - |
Net Income | - | - | - | - | - | - | - |
Avg Forecast | $-55.82M | $-67.58M | $-64.07M | $-57.93M | $-64.05M | $-60.91M | $-49.30M |
High Forecast | $-55.82M | $-67.58M | $-64.07M | $-57.93M | $-64.05M | $-56.51M | $-49.30M |
Low Forecast | $-55.82M | $-67.58M | $-64.07M | $-57.93M | $-64.05M | $-71.58M | $-49.30M |
Surprise % | - | - | - | - | - | - | - |
Nuvalent SG&A Forecast
Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
---|---|---|---|---|---|---|---|
# Analysts | - | - | - | - | - | - | - |
SG&A | - | - | - | - | - | - | - |
Avg Forecast | - | - | - | - | - | - | - |
High Forecast | - | - | - | - | - | - | - |
Low Forecast | - | - | - | - | - | - | - |
Surprise % | - | - | - | - | - | - | - |
Nuvalent EPS Forecast
Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
---|---|---|---|---|---|---|---|
# Analysts | - | - | - | - | - | - | - |
EPS | - | - | - | - | - | - | - |
Avg Forecast | $-0.86 | $-1.05 | $-0.99 | $-0.90 | $-0.99 | $-0.94 | $-0.76 |
High Forecast | $-0.86 | $-1.05 | $-0.99 | $-0.90 | $-0.99 | $-0.87 | $-0.76 |
Low Forecast | $-0.86 | $-1.05 | $-0.99 | $-0.90 | $-0.99 | $-1.11 | $-0.76 |
Surprise % | - | - | - | - | - | - | - |
Nuvalent Peer Comparison by Price Target
Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
---|---|---|---|---|---|
VTYX | Ventyx Biosciences | $2.29 | $33.86 | 1378.60% | Buy |
REPL | Replimune Group | $11.13 | $24.20 | 117.43% | Buy |
GPCR | Structure Therapeutics | $40.84 | $86.00 | 110.58% | Buy |
CGEM | Cullinan Oncology | $17.95 | $32.00 | 78.27% | Buy |
VRDN | Viridian Therapeutics | $22.06 | $37.83 | 71.49% | Buy |
TVTX | Travere Therapeutics | $13.48 | $21.60 | 60.24% | Buy |
KNSA | Kiniksa Pharmaceuticals | $25.26 | $37.00 | 46.48% | Buy |
ASND | Ascendis Pharma | $119.22 | $174.46 | 46.33% | Buy |
DICE | DICE Therapeutics | $47.55 | $60.00 | 26.18% | Buy |
NUVL | Nuvalent | $87.45 | $107.33 | 22.73% | Buy |
PCVX | Vaxcyte | $116.00 | $124.14 | 7.02% | Buy |
UTHR | United Therapeutics | $339.12 | $312.50 | -7.85% | Buy |
ACLX | Arcellx | $76.89 | $61.00 | -20.67% | Buy |
CERE | Cerevel Therapeutics | $44.96 | $33.50 | -25.49% | Buy |
NUVL Forecast FAQ
Is Nuvalent a good buy?
Yes, according to 4 Wall Street analysts, Nuvalent (NUVL) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 4 'Buy' recommendations, accounting for 100.00% of NUVL's total ratings.
What is NUVL's price target?
Nuvalent (NUVL) average price target is $107.33 with a range of $97 to $115, implying a 22.73% from its last price of $87.45. The data is based on 4 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Nuvalent stock go up soon?
According to Wall Street analysts' prediction for NUVL stock, the company can go up by 22.73% (from the last price of $87.45 to the average price target of $107.33), up by 31.50% based on the highest stock price target, and up by 10.92% based on the lowest stock price target.
Can Nuvalent stock reach $130?
NUVL's average twelve months analyst stock price target of $107.33 does not support the claim that Nuvalent can reach $130 in the near future.
What are Nuvalent's analysts' financial forecasts?
Nuvalent's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-174M (high $-170M, low $-185M), average SG&A $0 (high $0, low $0), and average EPS is $-2.697 (high $-2.629, low $-2.862). NUVL's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $13.17M (high $13.17M, low $13.17M), average EBITDA is $0 (high $0, low $0), average net income is $-245M (high $-245M, low $-245M), average SG&A $0 (high $0, low $0), and average EPS is $-3.798 (high $-3.798, low $-3.798).